Work

Lead-203 VMT-α-Neuroendocrine Tumor Scintigraphy: A Promising Theranostics Agent

Year: 2024

Type: article

Abstract: Targeted alpha therapy (TAT) using lead-212 (Pb-212)-labeled peptides presents an attractive option for the treatment of metastatic neuroendocrine tumors (NETs). As Pb-203 presents an accurate diagnostic surrogate to Pb-212, imaging with Pb-203-labelled peptides can be an important prerequisite to assess the feasibility of TAT with Pb-212-labelled agents. Here, we present the imaging data of a patient with metastatic NET with Pb-203 VMT-α-NET, a somatostatin receptor targeting agent, and demonstrate the matching distribution of Pb-203 VMT-α-NET with Ga-68 DOTANOC.

Source: Indian Journal of Nuclear Medicine

DOI: 10.4103/ijnm.ijnm_2_23

Authors: Parul Thakral, Ishita Barat Sen, Subha Shankar Das, Michael K Schultz, Jyotsna Kumari, CB Virupakshappa, Dharmender Malik

Institutions: Fortis Memorial Research Institute, University of Iowa

Language: English

Topic: Neuroendocrine Tumor Research Advances

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

OpenAlex ID: W4399134162

FWCI: 1.046

Cites: 6

Cited by: 4

Related to: 10